Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.47 |
| ▸ | CCR7 | P32248 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490008 | 0.90 | NPC1 (0.48) | CXCR2CCR7MEN1KMT2A | |
| SCHEMBL1487070 | 0.88 | CXCR2 (0.43) | CXCR2CCR7MEN1KMT2AMGAM | |
| SCHEMBL490197 | 0.88 | CXCR2 (0.49) | CXCR2MEN1KMT2AMGAMGAA | |
| SCHEMBL1487166 | 0.87 | CXCR2 (0.44) | CXCR2CCR7MEN1KMT2A | |
| SCHEMBL1487403 | 0.86 | TOP2A (0.39) | CXCR2CCR7MEN1KMT2AMGAM | |
| SCHEMBL489678 | 0.85 | MEN1 (0.45) | CXCR2MEN1KMT2AMGAMGAA | |
| SCHEMBL1487207 | 0.85 | CXCR2 (0.45) | CXCR2CCR7 | |
| SCHEMBL1487162 | 0.85 | CXCR2 (0.44) | CXCR2CCR7MEN1KMT2A | |
| SCHEMBL27624744 | 0.84 | KMT2A (0.45) | CXCR2CCR7KMT2A | |
| SCHEMBL1487377 | 0.84 | CXCR2 (0.49) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102796081-B | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB | 2015-04-22 | — | — | CN | disclosed |
| US-8722883-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1809624-B1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA R&D ALDERLY PARK (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8410123-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1809624-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006024823-A9 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006024823-A1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CCR7 20/4885MEN1 4811/4885 |
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | CXCR2 5/4885CCR7 15/4885MEN1 3902/4885 |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CCR7 20/4885MEN1 4811/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CCR7 20/4885MEN1 4783/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885CCR7 31/4885MEN1 3586/4885 |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CXCR2 4/4885CCR7 20/4885MEN1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.